Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.69 |
| ▸ | KDR | P35968 | 7/20 | 0.68 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.68 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.66 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.66 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.66 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.66 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.66 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.66 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.66 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.66 |
| ▸ | CSF1R | P07333 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6807507 | 1.00 | EGFR (0.69) | EGFRKDRERBB2HDAC3HDAC4 | |
| SCHEMBL27489469 | 0.91 | KDR (0.72) | EGFRKDRERBB2HDAC3HDAC4 | |
| SCHEMBL27489470 | 0.91 | KDR (0.72) | EGFRKDRERBB2HDAC3HDAC4 | |
| SCHEMBL7499449 | 0.91 | KDR (0.81) | EGFRKDRERBB2HDAC3HDAC4 | |
| SCHEMBL7499455 | 0.91 | KDR (0.81) | EGFRKDRERBB2HDAC3HDAC4 | |
| SCHEMBL7497282 | 0.90 | EGFR (0.82) | EGFRKDRERBB2HDAC3HDAC4 | |
| SCHEMBL7497288 | 0.90 | EGFR (0.82) | EGFRKDRERBB2HDAC3HDAC4 | |
| SCHEMBL8327218 | 0.89 | EGFR (0.67) | EGFRKDRERBB2HDAC3HDAC4 | |
| SCHEMBL4767497 | 0.89 | EGFR (0.67) | EGFRKDRERBB2HDAC3HDAC4 | |
| SCHEMBL7498147 | 0.89 | EGFR (0.71) | EGFRKDRERBB2HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043403-A1 | Use of transcription or translation products of genes the expression levels of which correlate with the biological activity of an EGFR tyrosine kinase inhibitor | FURST PETER (CH) | 2004-03-04 | — | — | US | claimed |
| EP-1346062-A1 | PROCESSES FOR DETERMINING THE BIOLOGICAL ACTIVITY OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2003-09-24 | — | — | EP | claimed |
| WO-2002050306-A1 | PROCESSES FOR DETERMINING THE BIOLOGICAL ACTIVITY OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2002-06-27 | — | — | WO | claimed |
| EP-0836605-B1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 2002-02-06 | — | — | EP | claimed |
| EP-0836605-A1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF | Novartis AG (CH) | 1998-04-22 | — | — | EP | claimed |
| WO-1997002266-A1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 1997-01-23 | — | — | WO | claimed |
| US-20040043403-A1 | Use of transcription or translation products of genes the expression levels of which correlate with the biological activity of an EGFR tyrosine kinase inhibitor | FURST PETER (CH) | 2004-03-04 | — | — | US | disclosed |
| EP-1346062-A1 | PROCESSES FOR DETERMINING THE BIOLOGICAL ACTIVITY OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002050306-A1 | PROCESSES FOR DETERMINING THE BIOLOGICAL ACTIVITY OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2002-06-27 | — | — | WO | disclosed |
| EP-0836605-B1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 2002-02-06 | — | — | EP | disclosed |
| US-6140332-A | Pyrrolopyrimidines and processes for the preparation thereof | NOVARTIS AG (CH) | 2000-10-31 | — | — | US | disclosed |
| EP-0836605-A1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF | Novartis AG (CH) | 1998-04-22 | — | — | EP | disclosed |
| WO-1997002266-A1 | PYRROLOPYRIMIDINES AND PROCESSES FOR THE PREPARATION THEREOF | NOVARTIS AG (CH) | 1997-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043403-A1 | Use of transcription or translation products of genes the expression levels of which correlate with the biological activity of an EGFR tyrosine kinase inhibitor | EGFR, ETF1, TCEA1 | EGFR 1/4885KDR 986/4885ERBB2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.